Executive Summary
Clinical research depends on data, but access to high-quality patient data remains one of the industry’s persistent challenges.
Clinical datasets can be fragmented, difficult to access, expensive to generate, and subject to strict privacy requirements. Limited representation of certain patient populations can also make it harder for researchers to understand how therapies may perform across diverse groups.
Synthetic data is emerging as a potential solution.
Synthetic data is artificially generated information designed to reproduce important statistical and structural characteristics of real-world datasets without directly representing identifiable individuals. In clinical research, it can be generated using statistical techniques, machine learning, or generative AI.
The technology can help researchers explore datasets, develop analytical models, test workflows, simulate clinical scenarios, and support collaboration while reducing some of the risks associated with directly sharing sensitive patient information.
Synthetic data does not replace real clinical evidence. Its value is in expanding what researchers can safely do before, alongside, and between real-world studies.
As pharmaceutical companies seek faster development cycles and greater use of AI, synthetic data could become an important component of the modern clinical research infrastructure.
Why Does Clinical Research Need Synthetic Data?
Clinical research generates enormous amounts of sensitive information.
Patient records, laboratory results, imaging, genomic information, treatment histories, and trial outcomes can provide valuable insights. However, using these datasets often involves complex privacy, governance, consent, security, and access requirements.
These constraints can slow research and limit collaboration.
Synthetic data provides an alternative environment for certain activities.
Researchers can generate artificial datasets that preserve selected characteristics of real populations without exposing the original records. This can allow teams to develop algorithms, test analytical approaches, and identify potential patterns before working with sensitive production data.
The result can be a faster and more flexible research process.
What Is Synthetic Clinical Data?
Synthetic clinical data is artificially generated data designed to reflect characteristics of real clinical information.
It can include variables such as demographics, diagnoses, laboratory measurements, treatment histories, or simulated patient outcomes.
The generation process can use statistical models, machine learning, generative adversarial networks, or other AI techniques.
The quality of synthetic data depends on how accurately it reproduces the characteristics that matter for the intended use.
A dataset designed for software testing may require very different properties from one intended for research modeling.
Synthetic data should therefore be evaluated according to its specific purpose rather than treated as inherently equivalent to real patient data.
How Can Synthetic Data Improve Clinical Trial Planning?
Clinical trial planning is one area where synthetic data can be particularly useful.
Researchers can create virtual patient populations that reflect selected characteristics of a target disease population and use them to explore trial scenarios.
These simulations could help teams evaluate eligibility criteria, recruitment assumptions, visit schedules, and potential population distributions before launching a study.
Potential applications include:
- Trial feasibility analysis
- Patient population modeling
- Eligibility assessment
- Recruitment forecasting
- Protocol optimization
- Site planning
This can help sponsors identify potential problems earlier, when protocol changes are less expensive and easier to implement.
Can Synthetic Data Improve Patient Recruitment?
Patient recruitment is frequently constrained by the availability of eligible participants.
Synthetic populations can help sponsors estimate how different eligibility criteria could affect the size and characteristics of a potential trial population.
Researchers could simulate alternative inclusion and exclusion criteria and examine their potential impact before the study begins.
This does not provide a substitute for identifying actual patients.
Instead, it gives clinical development teams another tool for testing recruitment assumptions and identifying potentially restrictive protocol requirements.
Over time, this could support more feasible and patient-centered trial designs.
How Could Synthetic Data Support Underrepresented Populations?
Clinical datasets do not always represent every population equally.
Certain diseases, demographic groups, geographic regions, or clinical circumstances may be poorly represented in available datasets.
Synthetic data can potentially help researchers model underrepresented populations and explore how analytical models behave under different demographic or clinical conditions.
This could be particularly valuable for developing and testing AI systems.
However, synthetic representation should not be confused with real-world representation. If the underlying data lacks sufficient information about a population, synthetic generation cannot automatically recreate the missing biological or clinical reality.
Real-world data collection remains essential.
Can Synthetic Data Accelerate AI Development?
AI systems require substantial amounts of data for development and testing.
In healthcare, acquiring large datasets can be difficult because of privacy and access restrictions.
Synthetic data can provide a controlled environment for developing algorithms, testing software, and evaluating analytical workflows.
Researchers can also generate specific scenarios that may be rare in real datasets.
For example, synthetic data could help test how an algorithm responds to unusual combinations of clinical variables or simulate edge cases that are difficult to obtain at scale.
This can accelerate development while reducing reliance on direct access to sensitive datasets during early stages.
How Does Synthetic Data Protect Patient Privacy?
Privacy is one of the strongest arguments for synthetic data.
Because synthetic datasets are generated rather than directly copied from individual patient records, they can reduce exposure to identifiable information.
However, synthetic does not automatically mean anonymous or risk-free.
Poorly designed generation techniques can reproduce patterns too closely, potentially creating privacy concerns. Organizations therefore need appropriate privacy testing and governance before sharing or deploying synthetic datasets.
Synthetic data should be treated as a privacy-enhancing technology, not a universal guarantee of privacy.
What Role Could Synthetic Data Play in Clinical Trial Simulation?
Synthetic data can support increasingly sophisticated trial simulations.
Researchers can create artificial patient populations and model how different trial assumptions might influence potential outcomes.
This could help teams explore alternative designs before committing to a physical study.
When combined with digital twins and AI, synthetic populations could become even more sophisticated.
A sponsor could potentially model different patient characteristics, treatment scenarios, and operational conditions to identify which trial configurations are most promising.
The objective would be to reduce uncertainty before investing heavily in clinical execution.
Could Synthetic Data Reduce Clinical Research Costs?
Synthetic data may contribute to cost reduction by making certain development and analytical activities faster.
Teams could test software, develop analytical models, explore trial designs, and conduct preliminary feasibility assessments without repeatedly accessing expensive or tightly controlled clinical datasets.
However, synthetic data does not eliminate the need for real-world research.
Clinical trials, observational studies, and other sources of real patient evidence remain essential for demonstrating safety and efficacy.
The economic value therefore comes from improving the activities surrounding real-world research rather than replacing them.
What Are the Limitations of Synthetic Data?
Synthetic data has significant limitations.
A synthetic dataset can reproduce patterns found in its source data, including potential biases or gaps. If the underlying dataset is incomplete, the synthetic version may inherit those weaknesses.
There is also a risk of creating data that looks realistic but does not accurately represent biological relationships.
Researchers therefore need robust validation methods.
Synthetic data should be compared against appropriate real-world datasets to determine whether it is suitable for its intended application.
The more consequential the use case, the more rigorous that validation should be.
Will Regulators Accept Synthetic Data?
Regulatory acceptance will depend heavily on how synthetic data is used.
Using synthetic data for software development, testing, workflow design, or preliminary analysis is different from using it as evidence supporting a regulatory decision.
For high-stakes applications, regulators will need confidence that the generation methodology is scientifically sound and that the synthetic dataset accurately represents the characteristics relevant to the question being addressed.
This means pharmaceutical companies will need clear documentation around how synthetic datasets are generated, validated, governed, and used.
What Should Pharma Leaders Do Now?
Pharmaceutical companies should begin with clearly defined use cases where synthetic data can deliver practical value.
Software testing, AI development, trial simulation, workforce training, and preliminary analytical research can provide relatively controlled starting points.
Organizations should establish governance frameworks covering data provenance, generation methods, validation, privacy, access, and appropriate use.
Most importantly, teams should understand the distinction between synthetic evidence and real clinical evidence.
Synthetic data can accelerate research, but it cannot remove the need for trustworthy real-world observations.
What Is the Future of Synthetic Data in Clinical Research?
The future could involve synthetic data becoming a standard layer within clinical research infrastructure.
Sponsors could use synthetic populations to test protocols, train AI systems, develop analytics, and evaluate operational scenarios before working with sensitive patient data.
As generation techniques improve, synthetic datasets could become more representative and useful for increasingly sophisticated applications.
Combined with real-world evidence, digital twins, AI, and decentralized clinical technologies, synthetic data could help create a more flexible clinical research environment.
The most valuable systems will likely combine synthetic and real data rather than treating them as competing alternatives.
Conclusion
Synthetic data is changing clinical research by creating new ways to work with complex information while reducing some of the limitations associated with sensitive patient datasets.
It can support trial planning, recruitment analysis, AI development, clinical simulation, software testing, and research collaboration.
But synthetic data is not a replacement for real patient evidence. Its usefulness depends on the quality of the source data, the generation methodology, validation processes, and governance surrounding its use.
The strategic opportunity is to make clinical research more data-accessible without compromising trust.
As pharmaceutical companies increasingly rely on AI and advanced analytics, synthetic data could become an important bridge between the enormous potential of clinical information and the privacy, accessibility, and operational constraints that have traditionally limited its use.
Synthetic Data Expands Clinical Research Access
Synthetic data can reproduce useful statistical patterns from real patient datasets without directly exposing individual patient information. This can help researchers work with sensitive datasets while reducing some privacy and data-sharing barriers.
Clinical Research and Synthetic Control Arms
One promising application is the development of synthetic control arms. Instead of relying entirely on patients enrolled in a traditional control group, researchers can potentially use appropriately generated external data to support trial analysis. Recent research highlights synthetic control arms as an emerging Clinical Research use case, although methodology and regulatory acceptance remain important challenges.
Improving Patient Diversity in Clinical Research
Another potential advantage is the ability to model underrepresented populations and scenarios that may be difficult to collect at sufficient scale. Better-designed synthetic datasets could help researchers identify gaps in study populations and improve the testing of analytical approaches.
Challenges for Clinical Research
Synthetic data is not automatically equivalent to real patient data. Poorly generated datasets can introduce bias, lose clinically important relationships, or create unrealistic patient characteristics. Current research identifies validation, bias, governance, and public trust as major barriers to broader Clinical Research adoption.
The Future of Clinical Research With Synthetic Data
As generative AI and statistical modeling improve, synthetic data could become an important complement to traditional clinical datasets. However, its strongest role is likely to be alongside high-quality real-world and trial data rather than as a complete replacement. Strong validation, transparency, privacy testing, and regulatory oversight will remain essential.
Conclusion
Synthetic data is becoming an increasingly important technology for Clinical Research. By supporting privacy-conscious data sharing, trial simulations, AI development, and potential synthetic control groups, it could make research more flexible and efficient. At the same time, researchers must prove that generated datasets accurately preserve the clinical characteristics needed for reliable decisions.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
